• 28/01/2020

    SOS Stool method brings Xpert TB diagnosis closer to children

    Using stool samples to diagnose TB in children with Xpert is now recommended by the WHO. KNCV Tuberculosis Foundation is…

    Lees meer
  • 28/01/2020

    The story of Issayas

    On the outskirts of Addis Ababa in Ethiopia, toddler Issayas lives with his father and mother in a small weathered…

    Lees meer
  • 22/01/2020

    ASCENT announcement: Request for proposal

    The ASCENT project announces a Request for Proposals (RFP) for Provision of hosting services for the ASCENT Digital Adherence Platform.

    Lees meer
  • 13/01/2020

    ASCENT procurement announcement: Requests for quotation

    The ASCENT project has two requests for quotation (RFQ’s): 1. For printing of cardstock medication sleeves. 2. To facilitate incoming…

    Lees meer
  • 13/01/2020

    Resistant forms of TB: more patient-friendly treatment

    People suffering from resistant forms of tuberculosis (TB) can now be cured by more patient-friendly treatments. The World Health Organization…

    Lees meer
  • 12/01/2020

    TB Stigma Reduction Symposium

    INVITATION: Stigma and discrimination are recognized as some of the most commonly identified barriers to fight the Tuberculosis (TB) epidemic.

    Lees meer
  • 12/01/2020

    The story of Abdurahim

    Four-year-old Abdurahim from Kyrgyzstan is so small he looks half that age. He had spinal and intra-thoracic lymph node tuberculosis…

    Lees meer
  • 12/12/2019

    Start of a new era in fight against drug resistant TB

    WHO released a rapid communication on the treatment of drug resistant (DR) and extensively drug resistant (XDR) tuberculosis (TB). This…

    Lees meer
  • 20/11/2019

    7th European Advanced Course in Clinical Tuberculosis

    The 7th European Advanced Course in Clinical Tuberculosis (TB) offered an informative and interactive program with national and international speakers…

    Lees meer
  • 31/10/2019

    3HP regimen soon to be accessible in Malawi

    KNCV Tuberculosis Foundation Malawi welcomes the substantial reduction in the price of the anti-tuberculosis drug rifapentine, announced today at the…

    Lees meer
  • 31/10/2019

    Important price reduction improves access to TB prevention

    KNCV Tuberculosis Foundation welcomes the announcement of a substantial reduction in the price of an anti-tuberculosis medicine through the support…

    Lees meer
  • 25/09/2019

    Innovative TB treatment support project kicks off in the Philippines

    ASCENT aims to assist patients succeed in treatment using digital adherence technology. On World Lung Day, the innovative TB treatment…

    Lees meer
  • 01/09/2019

    Antacid helps tuberculosis bacteria to survive

    In 2017, some 10 million people suffered from tuberculosis and 1.6 million died of the disease. One reason why infection…

    Lees meer
  • Current recommended treatment regimen for highly drug-resistant TB (left) versus the BPaL regimen (right).

    14/08/2019

    FDA approval of BPaL regimen an important breakthrough in TB control

    The US Food & Drug Administration (FDA) today approved pretomanid for the treatment of highly drug-resistant forms of tuberculosis (TB)…

    Lees meer
  • 23/07/2019

    ASCENT: Empowering patients through digital technology

    GENEVA/THE HAGUE, The next three and a half years, KNCV Tuberculosis Foundation will lead the innovative ASCENT project, which stands…

    Lees meer

KNCV has been fighting TB since its establishment in 1903. Over the past 120 years, the organization has acquired indispensable knowledge and experience in the field of effective TB prevention and care, resulting in pre-elimination in the Netherlands and significant contributions to global evidence generation, policy development and TB program implementation worldwide.

Our experts
KNCV governance framework and integrity
Our patroness
Partner with us

Sorry

De versie van de browser die je gebruikt is verouderd en wordt niet ondersteund.
Upgrade je browser om de website optimaal te gebruiken.